• Parkinson’s disease (PD) is a neurodegenerative disorder featured by the loss of dopaminergic neurons in the substantia nigra.
    The primary motor symptoms of patients with PD are muscular rigidity, akinesia-bradykinesia and resting tremor.

    Haldol (catalepsy)

    Catalepsy is a well-known symptom of Parkinson's disease. It is characterized by muscle rigidity and fixity of posture for a prolonged period of time (akinesia).
    Haloperidol, a neuroleptic drug, induces catalepsy, and is thus used as a model for the screening of new compounds that could potentially reverse catalepsy and in that way improve certain symptoms of Parkinson’s disease.

  • Compound testing

    Anti-parkinsonian drugs are usually tested in this model but other treatments could also be considered. Please feel free to contact us to discuss the feasibility of your study.
  • Endpoints

    Haloperidol-induced catalepsy
    Akinesic symptoms of PD
  • The degree of inhibition / reversion of haloperidol-induced catalepsy is used to measure the potential effect of new drugs on akinesic symptoms of PD.

  • Graph A :

    Time course of Haloperidol-induced catalepsy in the mouse.
    Treatment with CSC markedly reduces haloperidol-induced catalepsy.

  • Graph B :

    Reduction of haloperidol-induced catalepsy by CSC during the stable phase (180-270min).

You could also be interested in